Since the earliest days of parenteralmanufacturingithas beenrecognized that manydrugsandbiologicswould notwithstand a physicalsterilizationprocessintheir finalcontainer.
The new manufacturing plant will be complementary to Angel's existing core business in advanced biologics, which includes biopharmaceutical proteins and cell therapies, such as stem cells.